Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Intracranial Hypertension, Elevated ICP (Intracranial Pressure)
Interventions: No Interventions; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Pulmonary Arterial Hypertension
Interventions: Coenzyme Q-10 in Pulmonary Hypertension subjects, Coenzyme Q-10 in Normal Control subjects; Dietary Supplement
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases
Interventions: Pioglitazone 30mg, Placebo, Labs; Drug · Diagnostic Test
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pregnancy Related, Hypertension in Pregnancy, Blood Pressure
Interventions: Alternate Nostril Breathing, Bhramari Breathing, Sheetali Breathing; Behavioral
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 18 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Merriam, Kansas

Conditions: Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease
Interventions: Liraglutide or Placebo; Drug
Lead sponsor: Tulane University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Diabetes Mellitus Type II, Hypertension
Interventions: Integrated CHW Intervention, CHW Session 1 Only; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Primary Open-angle Glaucoma, Ocular Hypertension
Interventions: OPA-6566, Placebo, Latanoprost; Drug
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: Artesia, California • Glendale, California • Roswell, Georgia + 6 more

Conditions: Hypertension
Interventions: Valsartan/Hydrochlorothiazide, HCTZ; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Pulmonary Arterial Hypertension
Interventions: Imatinib, Sildenafil, Bosentan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Tampa, Florida • Weston, Florida • Mineola, New York

Conditions: Glaucoma, Ocular Hypertension
Interventions: latanoprost 0.005% ophthalmic solution, Travoprost 004% sterile ophthalmic solution, Bimatoprost .03% sterile ophthalmic solution; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 40
States / cities: Bellflower, California • Inglewood, California • San Diego, California + 31 more

Conditions: Elevated Blood Pressure, Hypertension
Interventions: Dietitian-Assisted DASH groceries, Self-directed shopping; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Arterial Hypertension
Interventions: Tadalafil- Tablet or Oral suspension; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 5
States / cities: Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 2 more

Conditions: Pulmonary Embolism, Pulmonary Hypertension, Thromboembolism, Right Ventricular Dysfunction
Interventions: Alteplase, EKOS; Drug · Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 89 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Bay Shore, New York • Queens, New York

Conditions: Hypertension
Interventions: Eat Well 6-months, Eat Well 12-months; Behavioral
Lead sponsor: Institute for Medical Research, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertension
Interventions: Advantage MX Module; Device
Lead sponsor: SunTech Medical; Network
Eligibility: 1 Month to 3 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Retina Disease, Glaucoma, Normal
Interventions: P200TE, Predicate Device; Device
Lead sponsor: Optos, PLC; Industry
Eligibility: 22 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan 10 mg tablet, once daily.; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 5
States / cities: Atlanta, Georgia • St Louis, Missouri • Las Vegas, Nevada + 2 more

Conditions: Glaucoma, AMD, Diabetic Retinopathy (DR)
Interventions: Chronic Disease Intervention CDI; Other
Lead sponsor: Interstat LLC; Other
Eligibility: 18 Years to 99 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Nocturia, Hypertension, Sleep Disturbance
Interventions: BBTI, PM antihypertensive dosing or Chronotherapy, AM antihypertensive dosing; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Glaucoma
Interventions: KDB/Phacoemulsification, Trabectome/Phacoemulsification; Procedure
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 95 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hypertension, Portal
Interventions: Avenciguat (BI 685509), Placebo matching Avenciguat (BI 685509); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Pasadena, California • Rialto, California • Miami Lakes, Florida + 3 more

Conditions: Pulmonary Hypertension, Systemic Sclerosis, Mixed Connective Tissue Disease, Heart Failure With Normal Ejection Fraction, Healthy
Interventions: No intervention. Biospecimen collection only; Other
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Hypertension, Pre-Hypertension
Interventions: Isometric Handgrip Training, Aerobic Exercise Training; Other
Lead sponsor: University Institute of Maia; Other
Eligibility: 65 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Stress, Psychological
Interventions: Stress and emotion management; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 40 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

A Continuous, Non-Invasive, Real-time Method for Estimating and Predicting Intracranial Hypertension

Coenzyme Q-10 and Pulmonary Arterial Hypertension

Bioenergetic Effect of Pioglitazone in CLD-PH

Deep Breathing Techniques (Pranayama) in Pregnancy

To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study

Scaling Telehealth Models to Improve Co-morbid Diabetes and Hypertension (Phase II)

Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US

Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension

A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension

Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE

'Eat Well' Produce Prescription RCT

Clinical Validation of Suntech Advantage MX With Suntech Neonate and Children Cuff Line

P200TE Agreement and Precision Study

Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome

A Real-World Study of Interventional Clinical Outcomes in Patients With Open Angle Glaucoma and Other Chronic Eye Diseases

Sleep, Hypertension, and Nocturia: a Multicomponent Approach for Comorbid Illnesses

Effect of Intra-subject Phaco/Trabectome vs. Phaco/Kahook Dual Blade on Intraocular Pressure

A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

New Orleans Pulmonary Hypertension Biobank

The Hypotensive Effects of Home-Based Isometric Handgrip Training in Older Adults With Pre-Hypertension and Hypertension - The HoldAge Trial

OUR Stress/ Emotion Management for Black/African American Women With Hypertension